These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 38791887)

  • 1. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy.
    Olaoba OT; Adelusi TI; Yang M; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
    Bhandari K; Ding WQ
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma.
    Singh G; Kutcher D; Lally R; Rai V
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Therapies for Pancreatic Ductal Adenocarcinoma.
    Sally Á; McGowan R; Finn K; Moran BM
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of epigenetics in pancreatic ductal adenocarcinoma.
    Pandey S; Gupta VK; Lavania SP
    Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
    Kung HC; Yu J
    MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
    Ercan G; Karlitepe A; Ozpolat B
    Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
    Guo S; Wang Z
    Front Oncol; 2024; 14():1349308. PubMed ID: 38590651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
    Carozzo A; Yaneff A; Gómez N; Di Siervi N; Sahores A; Diez F; Attorresi AI; Rodríguez-González Á; Monczor F; Fernández N; Abba M; Shayo C; Davio C
    Mol Pharmacol; 2019 Jul; 96(1):13-25. PubMed ID: 31043460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of rhophilin 2 promotes pancreatic ductal adenocarcinoma.
    Bo W; Feng X; Tang X
    Oncol Lett; 2021 Jan; 21(1):76. PubMed ID: 33365087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities.
    Jain A; Bhardwaj V
    World J Gastroenterol; 2021 Oct; 27(39):6527-6550. PubMed ID: 34754151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.